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Abstract
Background: 2,5-Dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2)
inhibitor celecoxib (Celebrex®) that lacks COX-2-inhibitory function. However, despite its inability to block COX-2
activity, DMC is able to potently mimic the anti-tumor effects of celecoxib in vitro and in vivo, indicating that both of
these drugs are able to involve targets other than COX-2 to exert their recognized cytotoxic effects. However, the
molecular components that are involved in mediating these drugs' apoptosis-stimulatory consequences are incompletely
understood.
Results: We present evidence that celecoxib and DMC are able to down-regulate the expression of survivin, an anti-
apoptotic protein that is highly expressed in tumor cells and known to confer resistance of such cells to anti-cancer
treatments. Suppression of survivin is specific to these two drugs, as other coxibs (valdecoxib, rofecoxib) or traditional
NSAIDs (flurbiprofen, indomethacin, sulindac) do not affect survivin expression at similar concentrations. The extent of
survivin down-regulation by celecoxib and DMC in different tumor cell lines is somewhat variable, but closely correlates
with the degree of drug-induced growth inhibition and apoptosis. When combined with irinotecan, a widely used
anticancer drug, celecoxib and DMC greatly enhance the cytotoxic effects of this drug, in keeping with a model that
suppression of survivin may be beneficial to sensitize cancer cells to chemotherapy. Remarkably, these effects are not
restricted to in vitro conditions, but also take place in tumors from drug-treated animals, where both drugs similarly
repress survivin, induce apoptosis, and inhibit tumor growth in vivo.
Conclusion: In consideration of survivin's recognized role as a custodian of tumor cell survival, our results suggest that
celecoxib and DMC might exert their cytotoxic anti-tumor effects at least in part via the down-regulation of survivin –
in a manner that does not require the inhibition of cyclooxygenase-2. Because inhibition of COX-2 appears to be
negligible, it might be worthwhile to further evaluate DMC's potential as a non-coxib alternative to celecoxib for anti-
cancer purposes.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) have
long been implicated in the treatment or prevention of
various types of cancer. The biochemical mechanism gen-
erally ascribed to this effect is the inhibition of cyclooxy-
genase (COX) enzymes, which catalyze the initial step in
prostaglandin synthesis [1-3]. The traditional NSAIDs,
such as flurbiprofen, indomethacin, or sulindac, are able
to inhibit both COX-1 and COX-2 enzymes, while new
generation drugs, such as celecoxib (Celebrex®), val-
decoxib (Bextra®), or rofecoxib (Vioxx®), inhibit only
COX-2. Due to their more selective function, these latter
drugs, referred to as coxibs, initially had promised to offer
the therapeutic benefit of traditional NSAIDs with less of
the associated side effects [4-7]; however, this expectation
has come under intense scrutiny and has generated con-
siderable controversy in the recent past [8-10].
Celecoxib is widely prescribed under the trade name Cele-
brex® for relief of symptoms of osteoarthritis and rheuma-
toid arthritis and was also approved as an adjunct to
standard care for patients with familial adenomatous
polyposis (FAP). It is suspected that this drug might be
useful for the prevention and treatment of colorectal and
possibly other types of cancer, and several clinical trials
are ongoing to confirm this expectation. In addition,
celecoxib has demonstrated potent anti-cancer activity in
various animal tumor models in the laboratory [11-17].
Despite these promising results, however, the underlying
molecular mechanisms by which celecoxib exerts its anti-
tumor potential are not completely understood, in partic-
ular because of numerous reports describing potent anti-
proliferative and pro-apoptotic effects of this drug in the
absence of any apparent involvement of COX-2 [18-24].
In order to investigate the COX-2 independent anti-tumor
mechanisms of celecoxib in greater detail, we and others
have generated close structural analogs of this compound
that lack the ability to inhibit COX-2 activity [25-28]. One
such analog is 2,5-dimethyl-celecoxib (DMC), a com-
pound that was first developed in the laboratory of Ching-
Shih Chen at Ohio State University [26,28]. Intriguingly,
despite its inability to inhibit COX-2, DMC is able to
faithfully mimic – without exception – all of celecoxib's
numerous anti-tumor effects that have been investigated
so far, including the reduction of neovascularization and
the inhibition of experimental tumor growth in various in
vivo tumor models [21,25,26,28-32]. Therefore, DMC
appears to be well suited for studies intended to illumi-
nate the COX-2 independent anti-tumor effects of
celecoxib [33].
Because celecoxib and DMC are potent inducers of apop-
tosis, we investigated their effects on survivin, which is a
member of the inhibitor of apoptosis (IAP) family of pro-
teins that has been implicated in the control of cell divi-
sion and apoptosis [34]. Survivin's function in mitosis is
to preserve the mitotic apparatus and to allow normal
mitotic progression, whereas its anti-apoptotic function is
executed via its ability to prevent caspase activation. The
protein is usually not expressed in differentiated normal
adult tissues, but is elevated in the majority of human can-
cers, with very high levels generally being predictive of
tumor progression and poor prognosis. In addition, sur-
vivin appears to be involved in tumor cell resistance to
some anticancer agents and ionizing radiation (for
detailed references, see reviews [35-37].
As the above-described characteristics established survivin
as a potential target for anticancer therapy, we investi-
gated whether the expression of this anti-apoptotic pro-
tein could be restrained by celecoxib and DMC. Here we
report that both drugs are able to down-regulate survivin
expression and induce apoptosis in numerous tumor cell
lines. These effects are not restricted to in vitro conditions,
but also take place in drug-treated animals in vivo, where
both drugs repress survivin and induce apoptosis in
xenograft tumor tissue. Thus, in consideration of sur-
vivin's recognized role as a guardian of tumor cell survival,
our results suggest that celecoxib and DMC might exert
their cytotoxic anti-tumor effects at least in part via the
down-regulation of survivin. Because DMC lacks COX-2
inhibitory function, these anti-tumor effects appear to
take place without the involvement of celecoxib's well-
known target, cyclooxygenase-2.
Results
Celecoxib and DMC down-regulate survivin protein levels
To determine whether celecoxib and DMC would be able
to affect survivin expression in a variety of human tumor
types, we treated a collection of derived cell lines with
either drug in vitro. Because it had been established earlier
that DMC is generally more potent than celecoxib, we
used 30 and 50 µM of DMC, and 40 and 60 µM of
celecoxib. As shown in Figure 1, both drugs were able to
down-regulate survivin expression in all cell lines investi-
gated, which included cells derived from glioblastoma,
lymphoma, multiple myeloma, and carcinoma of the
breast, colon, and prostate. Consistent with earlier studies
on other targets, DMC exerted stronger effects than
celecoxib and caused a more potent down-regulation of
survivin. Although this effect was observed in all cell
types, the overall magnitude of down-regulation varied
between individual cell lines; for example, whereas Raji
lymphoma, T98G glioblastoma, and T47D breast carci-
noma cells displayed a very strong down-regulation of
survivin, LN229 glioblastoma, MCF7 breast carcinoma,
and HCT116 colon carcinoma showed a weaker response
at the same concentrations. However, further increased
concentrations of these two drugs invariably led to com-Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
Page 3 of 16
(page number not for citation purposes)
plete downregulation of survivin expression in all cell
lines examined, i.e., 60–70 µM DMC or 70–80 µM
celecoxib completely suppressed survivin expression,
which was accompanied by severe cytotoxicity (not
shown).
Down-regulation of survivin is independent of p53
Because the above results indicated a certain cell type-spe-
cific sensitivity with regards to the down-regulation of sur-
vivin, we comparatively analyzed several relevant
parameters in these cell lines. As it has been shown earlier
that the status of the tumor suppressor p53 might influ-
ence basal levels of survivin expression [38,39], we inves-
tigated whether there was a correlation of p53 status with
the basal and/or the differential drug-reduced levels of
survivin. As can be seen in Figure 2A, the basal level
expression of survivin, i.e., the cellular amount of survivin
protein in the absence of drug treatment, varied greatly
among the various tumor cell lines. However, overall
there was no obvious correlation between this variation of
basal level expression and the efficacy of drug-induced
repression (compare to Figure 1). But when the muta-
tional status of the p53 gene in these cell lines was inves-
tigated from data of the published literature (presented at
the top of Figure 2A), and was compared among cell lines
of the same tumor type, it appeared that the presence of
mutant p53 exerted a small, yet noticeable influence on
the efficacy of survivin down-regulation by DMC and
celecoxib in some of the cells. For example, in the pair of
breast carcinoma cell lines MCF7 (p53 wt) and T47D (p53
mut), T47D displayed a higher basal level (Figure 2) and
stronger down-regulation of survivin than MCF7 (Figure
1). The same held true among the various glioblastoma
cell lines we investigated: T98G and U251 (both p53 mut)
displayed higher basal levels and a somewhat stronger
down-regulation of survivin than U87 and LN229 (both
p53 wt). Similarly, the colon carcinoma pair HCT116
(p53 wt) and DLD-1 (p53 mut) followed this pattern as
well, although in this case the difference was less pro-
nounced.
However, the correlation between p53 status and basal
and drug-reduced survivin levels did not hold true in all
cell lines. For example, the pair of prostate carcinoma cell
lines, MIA-PaCa-2 and Bx-PC-3, displayed a noticeable
difference in their basal levels of survivin and in their
response to the drugs, even though these cells both harbor
mutant p53. Therefore, in order to distinguish whether
the observed differential drug responses were indeed
related to p53, or rather were an expression of the general
genetic heterogeneity of these aneuploid tumor cells, we
used an HCT116 colon carcinoma cell line where the p53
gene (or one of its crucial target genes, the cyclin-depend-
ent kinase inhibitor p21Waf1, which was found to mediate
p53's repression of survivin [40]) was disrupted by tar-
Celecoxib and DMC decrease levels of survivin protein in  various cancer cell lines Figure 1
Celecoxib and DMC decrease levels of survivin pro-
tein in various cancer cell lines. Several different cancer 
cell lines were cultured in the presence of celecoxib (Cxb) 
and DMC for 48 hours as indicated. Total cellular lysates 
were prepared and analyzed by Western blot analysis with 
specific antibodies to survivin. As a control for equal loading, 
all blots were also analyzed with antibodies to actin (only 
two of these control blots are shown at the bottom). The 
tumor type of each cell line is indicated on the right.Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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geted homologous recombination [41,42]. As shown in
Figure 2B, inactivation of p53 resulted in a minor reduc-
tion of drug effects, whereas inactivation of p21 had no
effect. Thus, taken together, we conclude that p53 does
not play a major role in the observed differential down-
regulation of survivin by celecoxib or DMC.
Down-regulation of survivin is independent of 
cyclooxygenase-2
Another parameter we decided to analyze in the various
tumor cell lines was cyclooxygenase-2 (COX-2). Although
the use of DMC, which does not inhibit COX-2, already
indicated that this enzyme quite likely played no role in
Basal level expression of survivin and Cox-2 proteins in various cancer cell lines and effect of p53 and p21 Figure 2
Basal level expression of survivin and Cox-2 proteins in various cancer cell lines and effect of p53 and p21. In 
(A), the various cancer cell lines were cultured in the absence of any drug treatment, harvested in log phase, and analyzed by 
Western blot analysis with antibodies to survivin, cycloxygenase-2 (Cox-2), and actin (as a loading control). In addition, the p53 
status of each line (as reported in a variety of reports) is indicated (wt: wild type; m: mutant). (Note that in LN229 cells, wt p53 
function is retained, despite a mutation in the coding sequence.) In (B), three variants of HCT116 colon carcinoma cells were 
treated with celecoxib (Cxb) or DMC and analyzed by Western blot analysis for survivin levels and actin (as a loading control; 
only one representative panel is shown). The top panel shows results with HCT116 cells that harbor wild type alleles of the 
p53 and p21 genes; the second panel is from cells with disrupted p53 alleles (p53-/-); the third panel is from cells lacking p21 
(p21-/-).Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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the observed drug effects, we determined the levels of
COX-2 protein and investigated whether they would cor-
relate with the sensitivity of these cells to DMC and/or
celecoxib. The amount of COX-2 protein was established
by Western blot analysis and is shown in Figure 2A. How-
ever, when compared to the data presented in Figure 1, we
found that cell lines with elevated levels of COX-2 (U87,
LN229, Bx-PC-3) did not consistently differ in their extent
of survivin down-regulation as compared to cell lines
lacking COX-2 (Raji, RPMI/8226, HCT116, MIA-PaCa-2).
Thus, as expected, no correlation between COX-2 expres-
sion and the degree of survivin down-regulation by DMC
or celecoxib was found.
The lack of COX-2 involvement was further confirmed by
comparing the effects of DMC and celecoxib to other
established inhibitors of this enzyme. For instance, flurbi-
profen, indomethacin, and sulindac are traditional
NSAIDs that inhibit both COX-1 and COX-2, whereas val-
decoxib and rofecoxib are coxibs that selectively inhibit
only COX-2. When two different tumor cell lines were
treated with various concentrations of the above inhibi-
tors, no effect on survivin expression was observed, even
at concentrations of up to 100 µM (Figure 3, bottom part),
which are more than double the effective concentrations
of celecoxib and DMC. Thus, the significant down-regula-
tion of survivin by DMC and celecoxib could not be
achieved by comparable concentrations of other COX-2
inhibitors, clearly arguing against an involvement of
COX-2 in these processes. In addition, none of these other
COX-2 inhibitors was able to substantially impinge on
cell growth and survival of these cells (Figure 3, top part),
nor were these compounds able to induce apoptosis at
these concentrations (not shown). Thus, the differential
Downregulation of survivin is specific to celecoxib and DMC and correlates with reduced survival Figure 3
Downregulation of survivin is specific to celecoxib and DMC and correlates with reduced survival. U251 glioblas-
toma or BxPc-3 pancreatic carcinoma cells were cultured in the presence of DMC, various non-steroidal anti-inflammatory 
drugs (NSAIDs), or solvent DMSO alone, at the concentrations indicated. Cell growth and survival was determined by stand-
ard MTT assay (top part of figure). In parallel, total cellular lysates were prepared and analyzed by Western blot analysis with 
specific antibodies to survivin or to actin as a loading control (bottom part of figure).Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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effects of DMC, celecoxib, and other coxibs and tradi-
tional NSAIDs indicated a correlation between the effects
on survivin expression and cell survival or death.
Down-regulation of survivin involves transcriptional 
repression
We had shown earlier that celecoxib and DMC are able to
inhibit the expression of two key cell cycle-regulatory
genes, cyclin A and cyclin B, at the transcriptional level
[20,25]. To determine whether survivin expression was
similarly affected by these drugs, we generated cells that
were stably transfected with luciferase reporter constructs
under the control of the survivin promoter. Two different
constructs were used; one contained 6270 bp of upstream
promoter sequences of the survivin gene, the other only
230 bp. As shown in Figure 4, the activity of both of these
constructs was similarly inhibited by DMC and celecoxib
(not shown for celecoxib), indicating that these drugs
were able to impinge on survivin transcription. As con-
trols, we used a reporter construct under the control of the
cyclin B promoter, which, as expected, was down-regu-
lated by DMC as well; however, a luciferase construct
under the control of the cytomegaloviral (CMV) promoter
was not affected, indicating that DMC (and celecoxib) did
not block transcription indiscriminately. Thus, we con-
clude that, in addition to cyclin A and cyclin B, survivin
represents yet another target of these drugs that is affected
at the transcriptional level.
Down-regulation of survivin correlates with increased 
apoptosis
Because survivin has a recognized role as an inhibitor of
apoptosis, we next investigated whether and how the
observed down-regulation of survivin by DMC would
relate to the known ability of this drug to induce apopto-
sis. We used several different representative cell lines
(U251, T98G, and LN229 glioblastoma; BxPc-3 and MIA
PaCa-2 pancreatic carcinoma) with differing sensitivities
to DMC, and comparatively analyzed their response to 30
and 50 µM DMC. As shown in Figure 5, U251, T98G, and
BxPc-3 cells responded quite sensitively; these cells dis-
played a potent down-regulation of survivin, and at the
same time strongly increased apoptosis in combination
with greatly reduced survival. On the other hand, at these
same concentrations of DMC, LN229 and MIA PaCa-2
cells exhibited only a minor down-regulation of survivin,
which correlated with marginally increased apoptosis and
a much weaker effect on overall cell survival (Figure 5).
Thus, the magnitude of survivin down-regulation caused
by DMC closely correlated with the extent of apoptosis
and with the degree of short-term growth and survival (as
determined by MTT assay), as well as long-term survival
(as determined by colony forming ability) of these cells.
Celecoxib and DMC enhance cell killing by CPT-11
With the use of the U251 and LN229 glioblastoma cell
lines, we next investigated whether DMC would be able to
synergize with other chemotherapeutic drugs to achieve
DMC decreases the activity of the survivin promoter Figure 4
DMC decreases the activity of the survivin promoter. Mass cultures of LN229 cells stably transfected with various luci-
ferase reporter constructs under the control of either the survivin promoter (-6270Surv and -230Surv), the cyclin B promoter, 
or the cytomegalovirus (CMV) promoter, were treated with different concentrations of DMC for 36 hours. Thereafter, cellu-
lar lysates were analyzed for luciferase activity. For each reporter construct, basal level activity in the absence of drug at 36 
hours was set to 100%. Shown is the mean (± SD; n = 3) luciferase activity from one experiment, which was repeated twice 
with similar results.Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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Downregulation of survivin by celecoxib and DMC correlates with increased apoptosis and reduced cell growth and survival Figure 5
Downregulation of survivin by celecoxib and DMC correlates with increased apoptosis and reduced cell growth 
and survival. The three glioblastoma cell lines U251, T98G, and LN229 (A), or the two pancreatic carcinoma cell lines BxPc-
3 and MIA PaCa-2 (B), were treated with 30 or 50 µM DMC or remained untreated for 48 hours. The effects on cell growth/
survival and on cell death were determined by various assays. The panels labeled Number of Colonies display the results from a 
colony forming assay, where the number of surviving cells able to spawn a colony of newly grown cells was determined; in this 
assay, the colonies of adherent cells were stained and visualized with methylene blue two weeks after drug treatment and were 
counted. The panels labeled % Cell Growth and Survival show the results from MTT assays performed at the end of the 48 hour 
drug treatment period. The panels labeled % Apoptotic Cells present the percentage of cells undergoing apoptosis as revealed by 
the TUNEL assay after 48 hours of drug treatment. At the bottom of each series of panels in A and B, the level of survivin pro-
tein at the end of drug treatment is shown, as determined by Western blot analysis with specific antibodies. Western blots for 
actin are also shown (as a loading control).Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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increased tumor cell killing. For this purpose, we used iri-
notecan (CPT-11) and temozolomide as two representa-
tive drugs that are commonly used for the treatment of
high-grade brain tumors [43] and determined tumor cell
survival with the use of the colony forming assay. Intrigu-
ingly, while DMC dramatically increased the cytotoxicity
of CPT-11, no such enhancing effect was observed in com-
bination with temozolomide (Figure 6). Furthermore, the
outcome was the same in both cell lines, U251 and
LN229, which are known to differ in the status of their
p53 and PTEN tumor suppressor genes [44,45] (and prob-
ably a few other genes as well). Thus, while this result
established that DMC is able to cause substantial chemo-
sensitization of glioblastoma cells with different genetic
backgrounds, it also revealed that this effect apparently
does not take place indiscriminantly with any type of anti-
cancer drug.
Celecoxib and DMC down-regulate survivin and induce 
apoptosis in vivo
Finally, we investigated whether the effects of DMC and
celecoxib on survivin expression would also take place in
vivo. For this purpose, we used a xenograft nude mouse
tumor model with subcutaneously implanted glioblast-
oma cells. After palpable tumors had developed, the ani-
mals received chow supplemented with either celecoxib,
DMC, or no drug (control group). As shown in Figure 7,
the group of animals that were treated with either
celecoxib or DMC displayed significantly (p < .01 and p <
.003, respectively) reduced tumor growth as compared to
the group of untreated animals, which was in keeping
with similar results published with the use of prostate car-
cinoma and Burkitt's lymphoma xenograft mouse tumor
models [21,25].
Representative tumors were collected from the animals
and analyzed by immunohistochemistry for survivin
expression and with the TUNEL assay for the presence of
apoptotic cell death. Typical results from the staining of
numerous tumor sections are presented in Figure 8 (bot-
tom half). For comparative purposes, we also performed
the same type of analysis on glioblastoma cells cultured
and treated with drugs in vitro (see top half of Figure 8).
Under in vitro conditions, and in keeping with the results
shown further above, celecoxib and DMC caused substan-
tial reduction of survivin expression, and at the same time,
increased levels of apoptotic cell death (Figure 8, top).
Tumor tissue obtained from control (non-drug treated)
animals stained strongly positive for survivin protein, and
at the same time, was apparently negative for the presence
Combination drug effects of DMC with CPT-11 or temozolomide Figure 6
Combination drug effects of DMC with CPT-11 or temozolomide. U251 and LN229 glioblastoma cells were treated 
with DMC, CPT-11, and temozolomide (TMZ) either alone or in combination as indicated for 48 hours. The percentage of sur-
viving cells was established by the conventional colony forming assay, where the number of surviving cells able to spawn a col-
ony of newly grown cells was determined two weeks after drug treatment. Shown are the results from one experiment 
performed in triplicate, which was repeated several times with very similar results.Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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of apoptotic cell death (Figure 8, bottom). In contrast,
tumor tissue from drug-treated animals displayed drasti-
cally reduced levels of survivin, to the point where not a
single positive cell could be found in tumors from DMC-
treated animals. Concomitantly, the tumor tissue from
drug-treated animals stained clearly positive for the pres-
ence of apoptotic cell death (Figure 8, bottom). Thus, in
agreement with the findings obtained in vitro, we found
that in vivo as well, both drugs were able to suppress sur-
vivin expression and concomitantly induce apoptosis in
tumor tissue.
Discussion
The selective COX-2 inhibitor celecoxib appears to hold
promise for the treatment and prevention of colorectal
cancer and possibly for other cancers as well. Because
COX-2 is an oncogene [46] and over-expressed in a large
number of tumors, it is generally thought that the COX-2-
inhibitory function of celecoxib is critical for its anti-
tumor property [4,47-49]. However, several recent studies
[19,21-24,27,50], including from our laboratory [20,51],
have indicated that celecoxib might be unique among the
class of coxibs because this particular compound appears
to be able to also suppress tumor formation in the
absence of COX-2 involvement. For example, all coxibs
completely inhibit COX-2 at very low micromolar con-
centrations in cell culture; yet only celecoxib causes effi-
cient growth arrest and induction of apoptosis at low
concentrations – an effect that is furthermore independ-
ent of the amount, or even the presence, of intracellular
COX-2 (i.e., it takes place even in cells that lack COX-2
protein) [20,23,26,30,50,52-54]. Additional strong sup-
port for COX-2-independent anti-tumor effects of
celecoxib has come from the use of its close structural ana-
log, 2,5-dimethyl-celecoxib (DMC) (.)[33], which lacks
COX-2 inhibitory function, yet was shown to faithfully
mimic the anti-tumor effects of celecoxib in various exper-
imental systems, including the reduction of neovasculari-
zation and the inhibition of experimental tumor growth
in prostate carcinoma and Burkitt's lymphoma xenograft
mouse tumor models [21,25,26,28-32].
The underlying mechanisms of celecoxib's (and DMC's)
COX-2 independent anti-tumor effects are not completely
understood, although several non-COX-2 targets have
been described that are affected by these two drugs in vitro
and in vivo [21,25-28,31,32]. In the present report, we
demonstrate that survivin, a protein that is critically
involved in the regulation of mitosis and the protection of
cells from apoptosis, is potently down-regulated by
celecoxib and by DMC in all tumor cell lines examined.
This effect appears to be independent of any involvement
of COX-2, as indicated by three observations: (i) both
drugs down-regulate survivin even in cells that do not
express detectable amounts of COX-2 (Figure 2A); (ii)
none of the other COX inhibitors tested, including the
coxibs rofecoxib (Vioxx) and valdecoxib (Bextra), are able
to impinge on survivin expression (Figure 3); (iii) DMC
does not inhibit COX-2, yet potently down-regulates sur-
vivin as well.
Inhibition of tumor growth by celecoxib and DMC in vivo Figure 7
Inhibition of tumor growth by celecoxib and DMC in vivo. Nude mice were implanted subcutaneously with U87 gliob-
lastoma cells, and two weeks later received daily chow supplemented with celecoxib, DMC, or no drug. Shown here is the 
increase in tumor volume over time (mean ± SD; n = 8). At the end of the experiment, the difference in mean tumor volume 
between the non-treated groups and the groups receiving celecoxib or DMC was statistically significant (p < .01 and p < .003, 
respectively). Shown are two independent experiments that were performed at different times with different batches of U87 
cells and different shipments of animals; therefore, a direct comparison between animals that received celecoxib and animals 
that received DMC is not possible.Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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Downregulation of survivin by celecoxib and DMC correlates with increased apoptosis in vitro and in vivo Figure 8
Downregulation of survivin by celecoxib and DMC correlates with increased apoptosis in vitro and in vivo. Top 
half: U87 glioblastoma cells were treated with celecoxib (Cxb) or DMC for 48 hours in vitro; thereafter, cytospins were per-
formed and the cells were subjected to immunohistochemical analysis of survivin protein levels and, in parallel, TUNEL assay 
for apoptotic cell death. Bottom half: tumor sections from animals described in Figure 7 were analyzed by immunohistochem-
istry for survivin expression and by TUNEL assay for apoptotic cell death. In all cases, representative sections are shown. Small 
black rectangles denote enlarged areas of the same photograph shown below. Arrows indicate examples of TUNEL-positive, 
i.e., apoptotic, cells.Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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There are a few reports from other groups [55-58] indicat-
ing that, in addition to celecoxib, some other NSAIDs
appear to be able to reduce survivin expression, and these
findings could be viewed as being discrepant to ours.
However, much higher concentrations were required; for
example, Zhang et al. [58] applied 200 µM of sulindac,
and Lin et al. [57] used 300 µM of etodolac to impact sur-
vivin expression. Compared to our results presented here,
these reports further emphasize our observation that
celecoxib and DMC are unique in that these two drugs are
able to suppress survivin expression at significantly lower
concentrations than other NSAIDs. Furthermore, studies
with the use of non-small cell lung cancer (NSCLC) cell
lines have indicated that increased COX-2 activity might
contribute to the stabilization of survivin in these cells
[59,60]. While these reports indicate a role of COX-2 in
the expression of survivin, it appears that this observation
cannot be generalized, as we have not observed a correla-
tion between COX-2 activity and the expression levels of
survivin in the various tumor cells lines used in our study
(Figure 2).
The potent down-regulation of survivin by celecoxib and
DMC, but not by other COX inhibitors, is reminiscent of
earlier reports demonstrating that only celecoxib and
DMC, but not other COX inhibitors, are able to efficiently
induce apoptosis at comparatively low concentrations
[21,25,26,28]. This correlation suggests that survivin
might be an important mediator of the cell death-induc-
ing function of celecoxib and DMC. Indeed, when we
compared the kinetics of survivin down-regulation with
the resulting increase in apoptosis in two cell lines with
varying sensitivities to DMC (Figure 5), we noticed a very
close correlation between the degree of survivin down-
regulation and the induction of apoptosis. In these cases,
stronger down-regulation of survivin by DMC was associ-
ated with substantially more efficient induction of apop-
tosis. These results are also consistent with our
observation (Figure 3) that those NSAIDs that did not
affect survivin expression (rofecoxib, valdecoxib, flurbi-
profen, and others) also did not impinge on cell growth
and survival and did not induce apoptosis.
In addition to survivin, there are several other intracellular
proteins that are known to restrain cell death when highly
expressed, such as, for example, Bcl-2, Bcl-xL, c-IAP2,
XIAP, and FLIP, which also have been found overex-
pressed in some tumors [61]. While our study did not
investigate the potential contribution of these compo-
nents, studies by others have excluded the involvement of
Bcl-2, Bcl-xL, Bax, Bad, or Bak in the apoptosis-stimulat-
ing mechanisms of celecoxib and several of its derivatives,
and instead provided evidence that these drugs appear to
function via the disruption of the mitochondrial mem-
brane potential [62]. This latter observation is of particu-
lar relevance, as it has been demonstrated that
suppression of survivin expression by RNA interference
causes loss of mitochondrial membrane potential and
spontaneous apoptosis [63]. Taken together, these data
consistently support our view that the observed down-reg-
ulation of survivin by celecoxib and DMC might consti-
tute an important step in the induction of apoptotic cell
death by these drugs.
Considering the well-known function of survivin as an
inhibitor of caspases and, consequently, as an anti-apop-
totic protein [35,64], it is not surprising that down-regu-
lation of this protein by celecoxib and DMC is associated
with increased cell death. It has been shown in several
other experimental systems that the down-regulation of
survivin expression, for example by antisense or siRNA
approaches [65], results in elevated "basal level" apopto-
sis and, perhaps more importantly, causes substantially
increased sensitivity of such tumor cells to killing by
chemotherapeutic drugs or ionizing radiation (for exam-
ples, see [66-71]). From these earlier results, one might
expect that the down-regulation of survivin by celecoxib
or DMC should sensitize these cells to other cancer drugs.
We tested this assumption with two widely used antican-
cer drugs, CPT-11 (irinotecan; Camptosar®) and temo-
zolomide (Temodar®). Intriguingly, while DMC vastly
increased cell killing by CPT-11, no such enhancing effect
was observed after co-treatment with temozolomide.
Thus, while these results establish proof-of-principle that
DMC can substantially enhance tumor cell killing by
other anticancer drugs, this obervation cannot be general-
ized and certainly deserves further study. In this context, it
should be noted that celecoxib has been shown previously
to enhance the anti-tumor efficacy of CPT-11 in a
xenograft mouse model in vivo [16], and a Phase II study
revealed encouraging activity of this drug combination
among heavily pretreated patients with recurrent malig-
nant glioma [72]. Considering the apparent mimicry of
celecoxib's anti-tumor effects by DMC, it might be worth-
while to explore the combination effects of CPT-11 and
DMC in greater detail. The potential advantages of evalu-
ating the non-coxib DMC for use in the clinic will be dis-
cussed further below.
Our efforts to understand the mechanisms by which DMC
accomplishes the down-regulation of survivin revealed
that at least part of this regulation occurs at the level of
transcription, i.e., our results clearly indicate that DMC is
able to potently inhibit survivin expression at the gene
level via the inhibition of promoter activity (Figure 4).
The extent of survivin promoter inhibition is comparable
to the transcriptional repression of the cyclin A and cyclin
B promoters by DMC and celecoxib, which we described
earlier and which represents a crucial component of the
cell cycle-inhibitory function of these two drugs [20,25].Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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Thus, similar to the negative regulation of cell cycle com-
ponents by these two drugs, transcriptional events also
appear to be involved in mediating their apoptosis-induc-
ing function (not shown for celecoxib).
Although the above described transcriptional events are
quite prominent, additional levels of survivin regulation
by celecoxib and DMC are likely. For example, it has been
shown that survivin protein is stabilized and protected
from degradation via its phosphorylation by the critical
cell cycle regulator, cyclin-dependent kinase (CDK). In
particular, phosphorylation on threonine-34 of the sur-
vivin protein, which is accomplished by the cyclinB/cdk1
complex, leads to substantial extension of survivin's half-
life during mitosis [73,74]. Conversely, it has been shown
that the inhibition of cyclinB/cdk1 activity by various
modes of intervention leads to increased turn-over and
loss of survivin protein [75-78]. In this regard, we have
recently demonstrated that the transcriptional down-reg-
ulation of cyclin A and cyclin B by celecoxib or DMC, as
mentioned further above, effects the complete loss of
enzymatic activity of the respective CDK complexes,
including cyclinB/cdk1 [20,25]. Thus, we surmise that in
addition to the transcriptional down-regulation of sur-
vivin expression, DMC and celecoxib also cause its
increased posttranslational degradation via the elimina-
tion of CDK enzymatic activity.
In the past, studies investigating the COX-2 independent
effects of celecoxib in vitro have been received with reser-
vations, due to the relatively high concentrations of drugs
that were required to generate such effects. While drug
concentrations between 10 to 80 µM are generally needed
to produce anti-proliferative and apoptosis-inducing
effects in cell culture in vitro, celecoxib concentrations
measured in the serum of patients or animals are in the
range of 3–10 µM [79-81]. Thus, this discrepancy has led
to the suggestion [17,82] that in vitro effects of celecoxib
(and perhaps DMC) might be an artifact and not reflective
of the mechanisms taking place in vivo. It was therefore
imperative for us to demonstrate whether or not the
down-regulation of survivin by celecoxib and DMC could
be recapitulated in an in vivo model. As convincingly
demonstrated by our results, both celecoxib and DMC
were able to potently inhibit survivin expression in
tumors of a xenograft mouse tumor model (Figure 8).
Even more so, similar to the events in our in vitro system,
the number of apoptotic cells in tumors from drug-treated
animals was substantially elevated. We therefore believe
that those drug-induced events that we documented
under elevated drug concentrations in vitro do not repre-
sent artifacts of the cell culture system, but rather are
reflective of events that also take place in vivo in drug-
treated animals.
The experimental use of DMC alongside celecoxib encom-
passes an important aspect that relates to the recently
revealed potentially life-threatening side effects of coxib
use in the clinic. The long-term use of coxibs at high dos-
ages – as believed to be necessary if used in anti-cancer
therapy – is troubled by severe, potentially life-threaten-
ing risks, such as cardiovascular events, renal injury, and
gastrointestinal toxicity [9,83-86]. Considering that these
side effects are believed to be a class effect due to the inhi-
bition of COX-2 and the resulting imbalance of prosta-
noids [8,87,88], it is tempting to speculate that the clinical
use of a celecoxib analog such as DMC, which lacks COX-
2 inhibitory function but maintains anti-tumor potency,
perhaps might avoid many of these unwanted side effects
– and possibly could be used at even higher dosages than
celecoxib for certain anti-tumor purposes.
Conclusion
It has become clear that at least parts of celecoxib's docu-
mented anti-tumor effects are mediated via mechanisms
that do not appear to involve COX-2. In this regard, our
study presents the anti-apoptotic and chemoprotective
protein survivin as an apparently important component
that is involved in mediating the drug's COX-2-independ-
ent induction of apoptotic tumor cell death. This provides
additional evidence that DMC, which does not inhibit
COX-2, is able to potently mimic all known anti-tumor
functions of celecoxib, and further supports our proposi-
tion [33] that it might be worthwhile to further evaluate
DMC's potential anti-cancer benefit in the clinic.
Materials and methods
Materials
Celecoxib is 4- [5-(4-methylphenyl)-3-(trifluoromethyl)-
1H-pyrazol-1-yl]benzenesulfonamide [89]. DMC is a
close structural analog, where the 5-aryl moiety has been
altered by replacing 4-methylphenyl with 2,5-dimethyl-
phenyl, resulting in 4- [5-(2,5-dimethylphenyl)-3-(trif-
luoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
[21,51]. Both compounds were synthesized in our labora-
tory according to previously published procedures; see ref.
[89] for celecoxib and ref. [51] for DMC. Each drug was
dissolved in DMSO at 100 mM (stock solution). In the
case of valdecoxib [90] and rofecoxib [91], commercial
caplets of Bextra®  (Pfizer, New York, NY) and Vioxx®
(Merck, Whitehouse Station, NJ), respectively, were sus-
pended in H2O to disintegrate the excipient, and the
active ingredient was dissolved in DMSO at 25 mM. In
addition, we used pure rofecoxib powder that was synthe-
sized in our laboratory according to established proce-
dures [92]. All traditional NSAIDs were purchased from
Sigma (St. Louis, MO) in powdered form and dissolved in
DMSO at 100 mM. All drugs were added to the cell culture
medium in a manner that kept the final concentration of
solvent (DMSO) below 0.5%.Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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Cell lines and culture conditions
Most cell lines were obtained from the American Tissue
Culture Collection (ATCC) and were propagated in
DMEM or RPMI (GIBCO BRL, Grand Island, NY) supple-
mented with 10% fetal bovine serum, 100 U/ml penicil-
lin, and 0.1 mg/ml streptomycin in a humidified
incubator at 37°C and a 5% CO2  atmosphere. The
HCT116 colon carcinoma cell line, and derivatives thereof
where the p53 tumor suppressor gene or the p21Waf1 gene
were disrupted by targeted homologous recombination
[41,42], were kindly supplied by Bert Vogelstein, Johns
Hopkins Oncology Center (Baltimore, MD). Some of the
glioblastoma cell lines were provided by Frank B. Furnari
and Webster K. Cavenee (Ludwig Institute of Cancer
Research, La Jolla, CA).
Immunoblots and antibodies
Total cell lysates were prepared by lysis of cells with RIPA
buffer [93], and protein concentrations were determined
using the bicinchoninic acid (BCA) protein assay reagent
(Pierce, Rockford, IL). For Western blot analysis, 50 µg of
each sample was processed as described [94]. The primary
antibodies were purchased from Cell Signaling Technolo-
gies (Beverly, MA), Cayman Chemical (Ann Arbor, MI), or
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and
were used according to manufacturer's recommendations.
The secondary antibodies were coupled to horseradish
peroxidase, and were detected by chemiluminescence
using the SuperSignal West substrate from Pierce. All
immunoblots were repeated at least once to confirm the
results.
Immunohistochemistry
Immunohistochemical analysis of protein expression in
tumor tissues and cell lines was performed with the use of
the Vectastatin ABC kit (Vector Laboratories, Burlingame,
CA) according to manufacturer's instructions. This proce-
dure employs biotinylated secondary antibodies and a
preformed avidin: biotinylated enzyme complex that has
been termed the ABC technique. As the primary antibody,
we used anti-survivin antibody (Santa Cruz Biotech)
diluted 1:100 in 2% normal goat blocking serum.
TUNEL staining
Apoptosis was measured quantitatively with the use of the
terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP nick end-labeling (TUNEL) assay [95]. All compo-
nents for this procedure were from the ApopTag In Situ
Apoptosis Detection kit (Chemicon, Temecula, CA),
which was used according to the manufacturer's instruc-
tions.
MTT assay
MTT assays were performed in 96-well plates as described
in detail elsewhere [31] with the use of 3.0–8.0 × 103 cells
per well.
Plasmids and stable transfections
The human LN229 glioblastoma cell line was stably co-
transfected with individual luciferase reporter plasmids
and the pSV2neo plasmid. The latter expresses the bacte-
rial aminoglycoside-3'-phosphotransferase (neo) gene
[96], which enables selection of transfected cells in
medium containing the aminoglycoside G418 sulfate.
Stable transfections were performed with the use of Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA), and mass cul-
tures of transfected cells were selected in G418 according
to standard protocols [97].
The following luciferase reporter plasmids were used. Cyc-
lin B-luc harbors 555 base pairs (bp) of upstream cyclin B
promoter sequences [98] and was kindly provided by Wil-
liam R. Taylor, Cleveland Clinic Foundation (Cleveland,
OH). CMV-luc is under the control of 880 bp encompass-
ing the promoter of cytomegalovirus (CMV) [20]. The sur-
vivin reporter plasmids -6270Surv-luc and -230Surv-luc
harbor 6270 bp and 230 bp, respectively, of the upstream
promoter region of the survivin gene [99] and were kindly
provided by the laboratory of Dario Altieri, Yale Univer-
sity (New Haven, CT).
Tumor growth in nude mice
All animal protocols were approved by the Institutional
Animal Care and Use Committee (IACUC) of the Univer-
sity of Southern California, and all applicable policies
were strictly observed during the course of this study.
Four- to six-week-old male athymic nu/nu mice were
obtained from Harlan (Indianapolis, IN) and kept in a
pathogen-free environment. To support more consistent
tumor take and uniform growth [100, 101], the animals
were whole-body irradiated with 300 cGy of ionizing radi-
ation (Cesium 137) four days prior to xenotransplanta-
tion by using a low dose-rate laboratory irradiator
(Gammacell 40; Atomic Energy of Canada Limited, Can-
ada).
For tumor inoculation, 5 × 105 U87 glioblastoma cells
were injected subcutaneously into the right flank. Once
palpable tumors had developed, the animals were ran-
domly divided into three groups: (i) treatment with
celecoxib (1,000 ppm in animal chow), (ii) treatment
with DMC (1,000 ppm in animal chow), and (iii) no drug
treatment (regular chow without drug added). The tumor
size in all animals was measured every three to four days.
Tumor size was calculated by the following formula: Vol-
ume (mm3) = L û W û H û 0.5 (L: length, W: width, H:Molecular Cancer 2006, 5:19 http://www.molecular-cancer.com/content/5/1/19
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height). Student t-test was used for statistical analysis, and
a P-value of <0.05 was considered significant.
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